Formulation and evaluation of sublingual tablets of losartan potassium
Clicks: 547
ID: 66474
2012
Article Quality & Performance Metrics
Overall Quality
Improving Quality
0.0
/100
Combines engagement data with AI-assessed academic quality
Reader Engagement
Steady Performance
79.2
/100
545 views
440 readers
Trending
AI Quality Assessment
Not analyzed
Abstract
Objective: Sublingual tablets of Losartan Potassium were prepared to improve its bioavailability,
to avoid pre-systemic metabolism in the gastrointestinal tract and hepatic first pass elimination.
Methods: The Sublingual tablets were prepared by direct compression procedure using
different concentration of Starch 1500 and microcrystalline cellulose. Compatibility studies of
drug and polymer were performed by FTIR spectroscopy and DSC. Preformulation property of
API was evaluated. Postcompressional parameters such disintegration time, wetting time, water
absorption ratio, in vitro drug release and in vivo bioavailability study of optimized formulation
were determined. Results: FTIR spectroscopy and DSC study revealed that there was no possible
interaction between drug and polymers. The precompression parameters were in acceptable
range of pharmacopoeial specification. The disintegration time of optimized formulation (F3) was
upto 48 sec. The in vitro release of Losartan Potassium was upto 15 min. The percentage relative
bioavailability of Losartan Potassium from optimized sublingual tablets was found to be 144.7 %.
Conclusions: Sublingual tablets of Losartan Potassium were successfully prepared with improved
bioavailability.
| Reference Key |
aghera2012formulationasian
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Aghera, Nikunj J.;Shah, Suresh D.;Vadalia, Kantilal R.; |
| Journal | asian pacific journal of tropical disease |
| Year | 2012 |
| DOI |
DOI not found
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.